Zymeworks enters global license agreement with Roche for ZW209 after stock ends session up 1%

Traders Union
All News
Business & Wealth
Companies
Zymeworks stock rises 1% today

Highlights

Zymeworks has secured an exclusive global license agreement with Roche for a DLL3-targeting cancer therapy worth up to $813 million in total potential payments, milestones, and royalties.
Zymeworks will receive a $55 million upfront payment and $40 million upon Phase 1b trial initiation, with global sales rights protected into the 2040s.
Zymeworks stock is up 1% on the day at $28.44, and 52 of 52 analysts rate the stock a buy with a median price target of $38.

Zymeworks has entered into an exclusive global license and collaboration agreement with Roche for ZW209, its DLL3-targeting trispecific T cell engager, as first announced on October 23, 2026. The company is set to receive a $55 million upfront payment and an additional $40 million upon initiation of the Phase 1b trial. The deal could bring Zymeworks up to $813 million in total consideration including milestones and royalties, with rights to global sales protected by patents into the 2040s, according to Global Banking and Finance.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Bullish momentum holds as shares test resistance with overbought signal

RSI at 61 is nearing overbought territory, suggesting the advance is becoming stretched. Price action remains broadly bullish, with shares holding above their MA-20, MA-50, and MA-200 levels. The nearest resistance is the weekly high at $28.91, which could be tested if buyers stay committed.

Odds favor upside over five days as buyers eye break above resistance

A move through the weekly high at $28.91 would indicate buyers are willing to follow through. RSI remains close to overbought, an early warning that further gains may be harder to sustain. Over the next five trading days, upside probability stands at 79% and downside at 21%, with an expected trading range of $26.69 to $30.18. The past week saw a sharp move higher but without a sustained trend; even so, continued strength from here would need to clear that resistance, while a drop below $27 would suggest the move is being faded. On the weekly chart the longer-term picture stays firmly constructive.

Previously it was reported that Zymeworks was experiencing persistent downside pressure, with technical indicators signaling an absence of near-term rebound momentum. The latest licensing agreement and subsequent price surge mark a clear shift in trend, and traders should now monitor the $28.91 resistance level for confirmation of ongoing bullish momentum or the potential for a near-term pullback.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.